299 related articles for article (PubMed ID: 32851421)
1. CDP-choline and galantamine, a personalized α7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
Psychopharmacology (Berl); 2020 Dec; 237(12):3665-3687. PubMed ID: 32851421
[TBL] [Abstract][Full Text] [Related]
2. An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Labelle A; Knott V
J Psychopharmacol; 2023 Apr; 37(4):381-395. PubMed ID: 36927273
[TBL] [Abstract][Full Text] [Related]
3. Combining CDP-choline and galantamine: Effects of a selective α7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
J Psychopharmacol; 2019 Jun; 33(6):688-699. PubMed ID: 30920339
[TBL] [Abstract][Full Text] [Related]
4. Combining CDP-choline and galantamine, an optimized α7 nicotinic strategy, to ameliorate sensory gating to speech stimuli in schizophrenia.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Labelle A; Knott V
Int J Psychophysiol; 2019 Nov; 145():70-82. PubMed ID: 30790597
[TBL] [Abstract][Full Text] [Related]
5. The acute dose and baseline amplitude-dependent effects of CDP-choline on deviance detection (MMN) in chronic schizophrenia: A pilot study.
Aidelbaum R; Labelle A; Choueiry J; Knott V
Exp Clin Psychopharmacol; 2022 Apr; 30(2):235-248. PubMed ID: 33630646
[TBL] [Abstract][Full Text] [Related]
6. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy.
Deutsch SI; Schwartz BL; Schooler NR; Brown CH; Rosse RB; Rosse SM
Schizophr Res; 2013 Aug; 148(1-3):138-44. PubMed ID: 23768813
[TBL] [Abstract][Full Text] [Related]
7. First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy.
Deutsch SI; Schwartz BL; Schooler NR; Rosse RB; Mastropaolo J; Gaskins B
Clin Neuropharmacol; 2008; 31(1):34-9. PubMed ID: 18303489
[TBL] [Abstract][Full Text] [Related]
8. Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy.
Deutsch SI; Rosse RB; Schwartz BL; Schooler NR; Gaskins BL; Long KD; Mastropaolo J
Eur Neuropsychopharmacol; 2008 Feb; 18(2):147-51. PubMed ID: 17656074
[TBL] [Abstract][Full Text] [Related]
9. Assessing the acute effects of CDP-choline on sensory gating in schizophrenia: A pilot study.
Aidelbaum R; Labelle A; Baddeley A; Knott V
J Psychopharmacol; 2018 May; 32(5):541-551. PubMed ID: 29338621
[TBL] [Abstract][Full Text] [Related]
10. CDP-choline: effects of the procholine supplement on sensory gating and executive function in healthy volunteers stratified for low, medium and high P50 suppression.
Knott V; Smith D; de la Salle S; Impey D; Choueiry J; Beaudry E; Smith M; Saghir S; Ilivitsky V; Labelle A
J Psychopharmacol; 2014 Dec; 28(12):1095-108. PubMed ID: 25315828
[TBL] [Abstract][Full Text] [Related]
11. Acute separate and combined effects of cannabinoid and nicotinic receptor agonists on MMN-indexed auditory deviance detection in healthy humans.
de la Salle S; Inyang L; Impey D; Smith D; Choueiry J; Nelson R; Heera J; Baddeley A; Ilivitsky V; Knott V
Pharmacol Biochem Behav; 2019 Sep; 184():172739. PubMed ID: 31283908
[TBL] [Abstract][Full Text] [Related]
12. Modulation of auditory deviance detection by acute nicotine is baseline and deviant dependent in healthy nonsmokers: a mismatch negativity study.
Knott V; Impey D; Philippe T; Smith D; Choueiry J; de la Salle S; Dort H
Hum Psychopharmacol; 2014 Sep; 29(5):446-58. PubMed ID: 25196041
[TBL] [Abstract][Full Text] [Related]
13. Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: Implications for schizophrenia.
Hamilton HK; D'Souza DC; Ford JM; Roach BJ; Kort NS; Ahn KH; Bhakta S; Ranganathan M; Mathalon DH
Schizophr Res; 2018 Jan; 191():87-94. PubMed ID: 28711472
[TBL] [Abstract][Full Text] [Related]
14. Nicotinic modulation of human auditory sensory memory: Evidence from mismatch negativity potentials.
Baldeweg T; Wong D; Stephan KE
Int J Psychophysiol; 2006 Jan; 59(1):49-58. PubMed ID: 16313986
[TBL] [Abstract][Full Text] [Related]
15. Stimulus-specific adaptation in auditory cortex is an NMDA-independent process distinct from the sensory novelty encoded by the mismatch negativity.
Farley BJ; Quirk MC; Doherty JJ; Christian EP
J Neurosci; 2010 Dec; 30(49):16475-84. PubMed ID: 21147987
[TBL] [Abstract][Full Text] [Related]
16. Maximizing the effect of an α7 nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits.
Stevens KE; Zheng L; Floyd KL; Stitzel JA
Brain Res; 2015 Jun; 1611():8-17. PubMed ID: 25744161
[TBL] [Abstract][Full Text] [Related]
17. Assessment of anodal and cathodal transcranial direct current stimulation (tDCS) on MMN-indexed auditory sensory processing.
Impey D; de la Salle S; Knott V
Brain Cogn; 2016 Jun; 105():46-54. PubMed ID: 27054908
[TBL] [Abstract][Full Text] [Related]
18. Deviance-Related Responses along the Auditory Hierarchy: Combined FFR, MLR and MMN Evidence.
Shiga T; Althen H; Cornella M; Zarnowiec K; Yabe H; Escera C
PLoS One; 2015; 10(9):e0136794. PubMed ID: 26348628
[TBL] [Abstract][Full Text] [Related]
19. The spatio-temporal dynamics of deviance and target detection in the passive and active auditory oddball paradigm: a sLORETA study.
Justen C; Herbert C
BMC Neurosci; 2018 Apr; 19(1):25. PubMed ID: 29673322
[TBL] [Abstract][Full Text] [Related]
20. Nicotinic modulation of auditory evoked potential electroencephalography in a rodent neurodevelopmental model of schizophrenia.
Kohlhaas KL; Robb HM; Roderwald VA; Rueter LE
Biochem Pharmacol; 2015 Oct; 97(4):482-487. PubMed ID: 26032639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
